Rep. David Taylor Sells Off Amgen Inc. (NASDAQ:AMGN) Stock

Key Points

• Rep. David Taylor sold Amgen shares worth between $1,001 and $15,000 on August 26, alongside sales of Vertex and Microsoft and purchases of Fifth Third Bancorp, Broadcom and American Electric Power.
• Amgen reported stronger-than-expected quarterly results, with EPS of $6.29 and revenue of $10.05 billion, while maintaining 2026 EPS guidance of $22.30–$23.50. The company also announced a quarterly dividend of $2.52 per share, representing a 2.3% annualized yield.
• Analysts maintain a consensus “Hold” rating with an average price target of $381.68. Investor concern increased after Novartis’ failed pelacarsen trial raised questions about the prospects for Amgen’s related olpasiran cardiovascular program.

Representative David Taylor (Republican-Ohio) recently sold shares of Amgen Inc. (NASDAQ:AMGN). In a filing disclosed on September 05th, the Representative disclosed that they had sold between $1,001 and $15,000 in Amgen stock on August 26th. The trade occurred in the Representative's "DAVID TAYLOR TRUST > SCHWAB JOINT BROKERAGE #1 (HOME GROWN)" account.

Representative David Taylor also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Vertex Pharmaceuticals NASDAQ: VRTX on 8/26/2026.
• Sold $1,001 - $15,000 in shares of Microsoft NASDAQ: MSFT on 8/26/2026.
• Purchased $1,001 - $15,000 in shares of Fifth Third Bancorp NASDAQ: FITB on 8/26/2026.
• Purchased $1,001 - $15,000 in shares of Broadcom NASDAQ: AVGO on 8/26/2026.
• Purchased $1,001 - $15,000 in shares of American Electric Power NASDAQ: AEP on 8/26/2026.
• Purchased $1,001 - $15,000 in shares of Installed Building Products NYSE: IBP on 8/14/2026.
• Sold $15,001 - $50,000 in shares of Microsoft NASDAQ: MSFT on 8/11/2026.
• Purchased $1,001 - $15,000 in shares of Procter & Gamble NYSE: PG on 8/11/2026.
• Purchased $1,001 - $15,000 in shares of Alphabet NASDAQ: GOOGL on 8/11/2026.
• Purchased $1,001 - $15,000 in shares of Broadcom NASDAQ: AVGO on 7/24/2026.

Amgen Price Performance

Amgen stock opened at $437.23 on Tuesday. Amgen Inc. has a 52 week low of $269.77 and a 52 week high of $447.03. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44. The stock has a market cap of $236.38 billion, a price-to-earnings ratio of 27.17, a PEG ratio of 3.15 and a beta of 0.43. The company's 50-day moving average price is $398.92 and its two-hundred day moving average price is $367.59.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping analysts' consensus estimates of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%.The company had revenue of $10.05 billion for the quarter, compared to the consensus estimate of $9.43 billion. During the same quarter in the previous year, the business earned $6.02 EPS. The company's quarterly revenue was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, analysts expect that Amgen Inc. will post 22.97 EPS for the current fiscal year.

Amgen Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be given a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date is Friday, August 21st. Amgen's dividend payout ratio is currently 62.65%.

Institutional Investors Weigh In On Amgen

Several hedge funds have recently modified their holdings of AMGN. Adell Harriman & Carpenter Inc. boosted its position in shares of Amgen by 7.9% during the 4th quarter. Adell Harriman & Carpenter Inc. now owns 22,008 shares of the medical research company's stock valued at $7,204,000 after acquiring an additional 1,609 shares in the last quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new position in Amgen in the fourth quarter worth about $22,441,000. Integrated Advisors Network LLC lifted its stake in Amgen by 50.5% during the first quarter. Integrated Advisors Network LLC now owns 18,941 shares of the medical research company's stock worth $6,664,000 after purchasing an additional 6,356 shares during the period. National Pension Service lifted its stake in Amgen by 4.7% during the fourth quarter. National Pension Service now owns 1,239,549 shares of the medical research company's stock worth $405,717,000 after purchasing an additional 55,489 shares during the period. Finally, KBC Group NV boosted its holdings in Amgen by 51.7% during the second quarter. KBC Group NV now owns 382,676 shares of the medical research company's stock valued at $138,574,000 after purchasing an additional 130,497 shares in the last quarter. 76.50% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. Argus lifted their price target on shares of Amgen from $375.00 to $460.00 and gave the stock a "buy" rating in a research report on Wednesday, August 19th. Sanford C. Bernstein raised their price objective on Amgen from $335.00 to $345.00 and gave the stock a "market perform" rating in a research note on Thursday, August 6th. Canaccord Genuity Group lifted their target price on Amgen from $366.00 to $384.00 and gave the stock a "hold" rating in a report on Wednesday, August 5th. The Goldman Sachs Group set a $389.00 target price on Amgen in a research report on Friday, June 5th. Finally, Citigroup upped their price target on shares of Amgen from $345.00 to $405.00 and gave the company a "neutral" rating in a research report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, thirteen have issued a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $381.68.

Key Headlines Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen continues to be viewed as a long-term growth candidate, supported by its diversified drug portfolio and potential pipeline contributions. However, the bullish commentary is largely based on broad fundamental and valuation screens rather than a new company-specific announcement. Why Amgen Is a Top Growth Stock for the Long-Term
• Neutral Sentiment: An industry report identified Amgen, Roche and Johnson & Johnson as leading participants in the expanding oncology bi/multispecific-drug market. The report offers sector context but does not announce a new Amgen asset, deal or clinical result, so its immediate effect on AMGN is likely limited. Bi/Multispecific Oncology Market Report
• Neutral Sentiment: Congressman David Taylor disclosed several trades, including sales of biotech holdings. These transactions are not directly linked to Amgen’s operations or outlook and do not provide a meaningful fundamental signal for AMGN. Congressional Stock Trades
• Negative Sentiment: Novartis reported that its Phase III pelacarsen study failed to reduce cardiovascular events, despite testing a lower target biomarker level. Investors are concerned that the result may challenge the broader “lipoprotein(a)” treatment mechanism and make it harder for Amgen’s 7,297-patient olpasiran outcome trial to produce a positive result. Amgen Shares Fall as Pelacarsen Misses Phase III Goal
• Negative Sentiment: The pelacarsen failure prompted a pullback in Amgen shares as investors reassessed olpasiran’s probability of success and potential commercial value. The concern is currently a pipeline-risk repricing, not evidence that Amgen’s approved products or recent earnings performance have deteriorated. Amgen’s 7,297-Patient Heart Bet Inherited a Higher Bar

Insider Activity at Amgen

In other news, SVP Rachna Khosla sold 1,252 shares of the stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $416.43, for a total value of $521,370.36. Following the completion of the transaction, the senior vice president directly owned 6,404 shares of the company's stock, valued at approximately $2,666,817.72. This represents a 16.35% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, SVP Nancy Grygiel sold 2,970 shares of the firm's stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the transaction, the senior vice president owned 7,340 shares of the company's stock, valued at $2,951,854.40. This trade represents a 28.81% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 6,222 shares of company stock worth $2,540,926. Corporate insiders own 0.85% of the company's stock.

About Representative Taylor

David Taylor (Republican Party) is a member of the U.S. House, representing Ohio's 2nd Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Taylor (Republican Party) ran for election to the U.S. House to represent Ohio's 2nd Congressional District. He won in the general election on November 5, 2024. David Taylor graduated from Amelia High School. Taylor earned degrees from Miami University (Ohio) and the University of Dayton School of Law. Taylor's career experience includes working as an attorney and as a businessman at Sardinia Ready Mix, Inc.

About Amgen

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.